uniQure updates Phase I/II clinical data for Huntington's disease program
uniQre N.V. presented an update on the Phase I/II trial of ifezuntirgene inilparvovec (AMT-130) for Huntington's disease, continuing to share long-term patient data and evaluation of biomarker effectiveness.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed